Discover the features of the interactive European Business ePaper PRESENT YOUR COMPANY OR SERVICE IN OUR NEXT EPAPER Give us a call! 0049 5971 921610 NAVIGATION At the bottom of the ePaper, you’ll find the navigation bar. Use the icons to navigate through the ePaper. -> Previous page   -> First page   -> Share  -> Search -> Zoom -> Next page   -> Last page Click the corners to flip pages. Click to zoom in  Picture gallery. Click on a picture to zoom in. Start a movie by clicking on the play button. www.european-business.com 2 2 European Business ePaper Digital issues of European Business – easily accessible and always available. No matter whether it is a special or a regular issue, take advantage of additional digital features such as clicking on a company’s link or connecting with a business via email.

Interview with Giuseppe Puntin, Managing Director of Ospedale Pederzoli SpA From nursing home to hospital Italy’s Servizio Sanitario Nazionale has provided generations of Italians with a good standard of universally accessible health services. Technical advances and demographic trends have helped to extend the average life expectancy. However, the system is today facing new chal- lenges. The country’s financial crisis has hit the health sector hard. Ospedale Pederzoli SpA in Peschiera del Garda is well aware of the new economical and ethical challenges. The health institution has successfully developed from a nursing home to a modern hospital. officially recognized as a hospital costs. These days, the future of for this area. It was literally a nurs- healthcare is jeopardized by the ing home and a hospital in the costs of services. We are facing same location.” the phenomenon of an ageing population and healthcare is con- Ospedale Pederzoli continually centrated on the last years of life. adapted to the changing require- There is a kind of cultural revolu- ments of modern medicine. Today, tion. In the past, you concentrated it is equipped with top-notch on curing the illness; then, pre- robots and earthquake-proof vention became a new topic, and features. “Three years ago, a re- today, healthcare is focused on the building project started that will be prolonging of one’s psychophysi- finished in two years’ time,” states cal well-being. As a consequence, Mr. Puntin. “Computerization and services are broadening which robotics ensure greater efficiency increases costs. Today’s wishes will compared to the past and reduce be the standard demands of to- Ten new operating theaters are equipped with state-of-the-art technology www.european-business.com 4 A classic room in the hospital which has 320 beds A public hospital which offers at beautiful Lake Garda,” says Mr. patients the service quality of a Puntin. “This region has two parts; private hospital – this has always the northern part is dominated by been the main guideline of Os- mountains and has a less con- pedale Pederzoli and its founder centrated population, while the Dr. Piero Pederzoli. “It all started in southern part is a popular tourist 1947 thanks to a doctor who had a attraction. Our establishment was dream,” explains Managing Direc- initially created as a nursing home tor Giuseppe Puntin. “His vision for surgery and other medical was to provide a reliable health services. As tourism developed, service to the people of his own our services broadened. In a very area.” short time the original 25 beds increased to 100. As a result, the Dr. Pederzoli’s vision has long center moved towards being a become reality. “We are located classic hospital, and in 1987 it was N A E P O R U E business

Interview with Vera Mogna, Business Development Director of Probiotical S.p.A. Restoring the natural balance The human intestine plays host to billions of bacteria that help it to perform its function of digesting the food we eat and absorbing nutrients into the bloodstream. However, a host of factors can disrupt the delicate balance of bacteria in the gut, leading to the kinds of intes- tinal problems such as bloating, cramping, diarrhoea and even more severe problems that affect so many people today. Probiotical S.p.A. is part of Group Movin Alce, a major Italian industrial and research concern active in the dairy industry. Probiotical exploits 30 years of research to produce probiotic lactic acid bacteria aimed at restoring the natural intestinal flora essential to healthy digestion. innovative research center dedi- while in the second we work to cre- cates an area covering 1,200 m2 to ate effective products using these a series of clean room laboratories strains in which we can assure the divided into production, sterile, strain’s individual properties until a fermentation, cryoprotection, defined expiry date.” freeze-drying, grinding, mixing and packaging areas as well as qual- Examples of functional probiotic ity control laboratories for product strains include strains that can analysis and batch certifications. produce vitamins such as B2, B12 “The focus of our research work is and folic acid, strains with an anti- both explorative and application- inflammatory action that can be based,” explains Ms. Mogna. “In used to treat IBS and IBD, strains the first instance, we are very with a strong action against e-coli, concerned with investigating new strains to treat infant gaseous colic probiotic strains with specific and strains with antioxidant and metabolic properties and functions anti-ageing complexes to protect Probiotial exhibits at a number of international fairs in Europe, Asia, the Middle East and America www.european-business.com 6 Probiotical was honoured with the Le Fonti award 2016 (from the left): Dott.ssa Vera Mogna, Consigliere di Amministrazione, and Dr. Giovanni Mogna, Presidente “We see ourselves as a research otical has the largest catalogue of centre that funds itself through probiotic strains of any company manufacturing, rather than as in its market. “We have roughly a production company that also 60 strains currently in production engages in research,” says Busi- out of a total bank of 250 strains,” ness Development Director Vera says Ms. Mogna. “By contrast, our Mogna. “Our research is the prime competitors have on average just reason for our existence. We invest six or seven strains.” 10% of our revenues in research and development each year in In order to bring a steady stream of order to find new ways in which we innovative new probiotic products can improve people’s health with to the market, Probiotical is com- good bacteria.” As a result of this mitted to an intensive programme primary focus on research, Probi- of research and development. Its N A E P O R U E business

Interview with Sándor Zettwitz, Managing Director of 77 Elektronika Kft. A Hungarian force in medical diagnostics Lifestyle changes over the last few decades have been both a blessing and a curse. On the plus side, we can celebrate vastly increased life expectancy. Unfortunately, improved access to processed foods and more sedentary living have also resulted in growing rates of diabetes, leading to demand for home blood glucose testing equipment. 77 Elektronika Kft. responded to this need and pioneered blood glucose meters for the Hungarian market. This remains among its key products today, which also include urine analyzers and consumables. produces devices for other OEMs, therapy accordingly.” This same as well. “In the meantime, we’ve service is available via the Internet. supplied 100,000 urine analyz- ers,” the Managing Director adds. The third generation of urine test- ers is making its debut while the 77 Elektronika continues to build fourth and fifth generations see on its original two pillars. Its latest continued research and devel- blood glucose meter does more opment prior to their respective than simply measure the glucose launches. “This kind of develop- levels in the blood; it stays in con- ment takes major investment,” Mr. nection with the doctor using Blue- Zettwitz says. “We’ve put in three tooth technology. “We save pa- billion HUF, about ten million EUR, tients hours of time normally spent to make it happen quickly. The in the waiting room,” Mr. Zettwitz next generations will bring even explains. “Our meters can send up more growth.” Development has 77 Elektronika is headquartered in Budapest József Lukács, a physicist, found- better devices. The company’s to 500 results, including the time proven to be one of 77 Elektroni- ed 77 Elektronika in 1986. At that blood glucose meters require just of testing, directly to the doctor so ka’s strengths time and again. “We time, there was no equipment in a drop of blood for analysis, and he or she can adjust the patient’s can make not only what the market Hungary to test blood glucose at its urine testing systems work us- home. After a neighbour – a doctor ing similar technology. “There are – showed him the kind of meters eleven important parameters that available in the United States, the determine the patient’s condition,” founder was inspired to produce Mr. Zettwitz explains. “Our first his own blood glucose meter. “It urine analyzer allowed doctors to wasn’t easy, but the measure- test those parameters within three ments were extremely accurate,” minutes with just the push of a says Sándor Zettwitz, Managing button. This small device filled a Director and brother-in-law of the gap in the healthcare market.” company’s founder. With the end Boehringer saw the tester and of communism in Eastern and requested its own model. 77 Elek- Central Europe, parts could be tronika developed the desired sourced from the west for even tester within six months and today The company offers a variety of models to suit the individual user’s needs N A E P O R U E business www.european-business.com 8

Interview with John Ridyard, Vice President, Marketing at Omnicell, Inc. Automation for better care Industrial automation is a concept often associated with assembly lines and replacing humans with machines for repetitive work. Health care, on the other hand, is a sector that involves empathy and sensitivity towards patients’ needs. At first glance, it seems like these two sectors have noth- ing in common, but in fact, automation can be instrumental in improv- ing patient care both in the hospital and at home. Omnicell, Inc., based in Mountain View, California, is a global recognized leader bringing automation to the healthcare sector, thereby increasing efficiency among hospital staff and to providers in the community. We spoke with John Ridyard, Vice President of Marketing at Omni- cell, about the company’s growth and how this industry is chang- ing in coming years. Omnicell, Inc. was founded in customers to provide a safe and Omnicell not only offers a system technology helps our customers 1992 by Randall Lipps, who effective way to distribute medi- that prevents errors in medica- optimize their supply chain, and continues as CEO, Chairman and cations by leveraging technology tion delivery, but also improves allows their staff to streamline President of the company, and is to overcome the limits of human efficiency. Hospital supply chain workflows, so they can spend a passionate advocate for patient beings’ best efforts,” Mr. Ridyard management presents similar more time on patient care,” Mr. care. While observing nurses explains. solutions for hospitals. “Using Ridyard highlights. care for his newborn daughter in the hospital, he noticed inef- ficiencies in their work regarding the amount of time they spent looking for supplies and admin- istering medication, and he real- ized that technology could be the solution to their problems. Just one year later, Omnicell in- stalled its first supply system in a hospital. The key to the com- pany’s solutions is the overarch- ing goal to improve healthcare economics and patient safety. “Humans make mistakes, the 1999 study ‘To Err is Human’ put that in the title. But when you are dealing with medica- tions, it’s imperative you do eve- rything you can to prevent these errors. Our solutions enable our N A E P O R U E business The company’s medication dispensing solutions reduce the possibility of human error www.european-business.com 10

erpabsnslyt Interview with Dr. Lionel Hadjadjeba, President Worldwide Commercial Operations and Corporate Senior Vice President of Accuray Improving life for cancer patients Cancer research is constantly developing more and more treatment options that help cancer patients to live longer and better lives. The number of patients diagnosed with cancer is still increasing, and therefore effective treatment options are more important than ever. Accuray Incorporated develops and produces a complete portfolio of innovative radiation therapy and radiosurgery platforms for treating multiple forms of cancer. With its high-precision cancer treatment solutions, tumours can be irradiated efficiently while preserving healthy tissue. This way, the side effects of the treatments can be reduced, and the quality of life of patients can be enhanced. Accuray is driven by its desire to mours anywhere in the body with the past can be re-treated with in 2011 to be able to work more help cancer patients live longer, high doses of radiation, so fewer our systems.” profitably. Accuray Incorporated, better lives without pain or suffer- sessions are needed to destroy with headquarters in California, ing. “Over the past 20 years, we the diseased cells,” explains Dr. Accuray was founded in 1990 by has developed into an interna- have brought to the market innova- Hadjadjeba. “CyberKnife® deliv- John R. Adler, who worked as a tional organization with customers tions for better cancer care,” says ers radiosurgery, and its unique neurosurgeon and professor at all over the world, a workforce of Dr. Lionel Hadjadjeba, President robotic architecture allows it to Stanford University. The company 1,000 people and annual revenue Worldwide Commercial Opera- treat tumours that are hard to acquired TomoTherapy Inc., which of 398.8 million USD in the fiscal tions and Corporate Senior Vice access surgically or are even was founded in 1999 and devel- year 2016. Accuray Europe SAS is President of Accuray. “Cancer has inoperable, in a pain-free way.” oped the TomoTherapy® System. the subsidiary led by Dr. Hadjad- evolved from a deadly disease into The TomoTherapy® System is The two companies joined forces jeba. “Our market is growing at a a chronic illness. We will continue based on a built-in CT platform to invest in cancer research and which is specifically designed for the further improvement of our integrated 3D image guidance. technologies.” With the TomoTherapy®, tumours in critical locations and of simple Each cancer patient has an indi- or complex shapes can be treated vidual clinical picture. That is why with accurate doses of radiation. individualized, tailor-made treat- “Thanks to our radiotherapy solu- ment options are so important in tions, surgery becomes no longer the treatment of cancer. With its necessary,” points out Dr. Hadj- TomoTherapy® and CyberKnife® adjeba. “Large body parts or even systems, Accuray offers two highly multiple tumours can be treated precise radiotherapy solutions for at the same time. And if the can- the full range of indications. “Our cer comes back, areas that have CyberKnife® is used to treat tu- been treated with radiotherapy in N A E P O R U E business The CyberKnife® System is a highly precise radiotherapy solution for a broad range of indications www.european-business.com 12

Interview with Arnaud Jérôme, CEO of ISIS Diabète SAS Hope for diabetes sufferers Diabetes diagnoses are rising, with an estimated 300 million suffer- ers worldwide. When left untreated or poorly managed, diabetes has terrible consequences for patients. However, maintaining stable blood sugar levels requires a level of discipline that many people struggle with. ISIS Diabète SAS in France specializes in fitting and training patients in the use of the latest external insulin pumps to free them from a constrictive regime. ISIS Diabète SAS 125 Avenue Louis Roche 92230 Gennevilliers France  +33 800 881156  +33 4 7984920  contact@isisdiabete.fr  www.isisdiabete.fr Diabetes is one of the major health Although the way to regulate blood advantage of the pump is that it diagnosed with diabetes at an ever challenges the world is facing today. sugar in diabetic patients is to reacts instantly to fluctuations in younger age, this is a vital step While the incidence of Type 1 dia- inject insulin, not every patient blood sugar in much the same way forward.” ISIS Diabète currently betes remains stable, the number is offered a pump by their doc- as a normal person’s body reacts, supports 4,000 diabetes patients, of new diagnoses of lifestyle-related tor. “In France there are around thus avoiding the chronic hyper- making it the sixth-largest provider Type 2 diabetes is rising exponen- 50,000 diabetes patients who have glycemia that is so damaging in in its niche. “We try to tailor our tially.Type 2 diabetes is closely pumps, and there are around 80 the long term. Since the catheter service to the patients’ needs, linked with the global explosion in providers like us who provide these only needs changing once every which are more demanding than obesity rates and is placing a huge patients with help and support in three days, it also greatly reduces the legal requirements,” adds Mr. burden on health systems around the optimum use of their pump,” the frequency with which patients Jérôme. “If a patient needs more the world. “Helping patients to man- explains Mr. Jérôme. “Most of must prick themselves with a nee- visits than are prescribed, then we age their diabetes successfully is the them are regionally active. We dle. “Insulin pumps are transform- key to lowering the burden on health are one of only a handful who are ing lives for the better and giving are happy to do them if it means the outcome is better.” ❙ providers and improving the long- active throughout France.” ISIS hope to diabetes patients that they term prognosis for sufferers,” says Diabète supplies patients with can avoid the amputations and CEO Arnaud Jérôme. “There are 3.5 the insulin pump and the cath- loss of sight which are the more  Read this article online webcode: 5747 million diabetes patients in France eter through which the insulin is severe consequences of a lifetime alone, of whom just 200,000 have delivered into the bloodstream of elevated blood sugar,” says Mr. Type 1 diabetes.” and trains them in its use. The Jérôme. “With more people being ISIS Diabète is keen to expand its market and increase the number of patients able to benefit from insulin pump technology Insulin pumps offer hope to diabetics by delivering insulin as it is needed and preventing jumps in blood sugar N A E P O R U E business www.european-business.com 14

Interview with Xavier Morge, General Director of Bertin Pharma A one-stop-shop for pharmaceutical development Pharmaceutical research is moving in many exciting directions that promise to bring real advances for human health, not just in the big medical challenges such as cancer and metabolic disease, but in im- munopharmacology and nutraceuticals as well. The backbone of the research process is exhaustive testing of new molecules and biologics. Bertin Pharma in France specializes in supplying a wide range of biore- agents and is also a respected research solution provider. Bertin Pharma distributes its biorea- gents under a number of brands to determine their mode of action and to predict their possible ad- verse effects (toxicity and off-target interactions). Once the drug is selected, Bertin Pharma proposes solutions to assess in animals and humans the toxicity and efficacy of the drug candidate. Our expertise relies on the right combination of highly experienced scientific staff with hyphenated drug analysis methods. This area accounts for 32% of turnover. This offer, with a high added value, revolves around innovation (from formulation to production of batches for clinical Bertin Pharma employs 140 people at four offices in France and offers a wealth of expertise in pharmaceutical development “We are a leading provider of re- Our daily ambition is to serve our largest of these areas is pharma- trials), immuno-pharmacology and search solutions serving a broad customers with our values ‘Care, ceutical development. Here, Bertin biosafety, and finally the evalua- customer base of leading phar- Innovate, Deliver’. It is a question Pharma intervenes throughout the tion of the fate of the drug. Bertin maceutical clients active in the of answering the stakes and ambi- value chain of the development Pharma accompanies firms in the production of generic, OTC and its tions of our clients by defining the of a molecule from the earliest success of their molecule whether ethical products,” explains Manag- program of work most appropriate stages, such as translational medi- of chemical or biological origin. ing Director and co-founder Xavier to their needs. Our R&D solutions cine, which aims to bridge the gap Morge. “We offer our expertise in include technical and scientific between science and benchlab In October of last year its efforts three main areas of competence: expertise but also the best possible and the manufacture of clinical in this area were recognized with pharmaceutical development, ser- scheduling of projects. Finally, our batches. Through drug discovery the award Best Research Solutions vices relating to drug metabolism commitment is to control delays, and translational research, Bertin Provider from Corporate LiveWire and pharmacokinetics (DMPK) costs and to deliver results that are Pharma’s objective is to evidence in its annual Healthcare & Life- and translational medicine for exploitable and convincing.” Ac- the efficacy of new molecules, Sciences awards. “The award infectious and immune diseases. counting for 55% of turnover, the drugs or biologics and vaccines from Corporate LiveWire is further N A E P O R U E business www.european-business.com 16

Interview with Stefano Camurri, Managing Director of Bomi Italia S.p.A. Handling health around the world Without the transport and logistics industry, the whole world would very quickly grind to a halt. No foodstuffs, no building materials, no medical supplies. Not just the luxuries in life need to be transported, the essentials which sustain life are equally dependent on efficient delivery solutions. Many products require only a lorry, ship or aircraft to get from A to B with no special conditions necessary, and there are thousands of generalist freight forwarders competing for this business. Some goods, however, need very careful handling due either to their value or sensitivity or, of course, both. Bomi Group specializes in logistics for the medi- cal sector, moving clinical machines, diagnostics and other products around the world. “In the logistics business, you have and specialized products for the to find your niche,” points out the medical industry, everything in fact Managing Director Stefano Camur- that a hospital or clinic needs with ri, who joined Bomi Group follow- the exception of pharmaceutical ing graduation and has spent the products. The company deals with past 20 years in various positions hundreds of producers of medical within the company. “If you want to devices across the world and man- successfully reduce costs and im- ages many different kinds of prod- prove service, you must have the ucts across the healthcare supply focus of a specialist. In the logistic chain. “Each of these products sector, the most important dynam- can save lives,” emphasizes Mr. Bomi Italia S.p.A. specializes in logistics for the medical sector ics are economies of scale and Camurri. “Often they are delivered procedure. We have developed a “We use our own fleet of vehicles, service. Our logistic niche is a little to the clinic for use with a specific robust process for tracking medi- a point which is becoming increas- more complicated; in fact we deal patient. We can’t make mistakes. cal devices. It is vital that we know ingly important,” adds the Manag- with life-saving products, which The goods have to be delivered on where they are at all times.” Not all ing Director. are regulated by strict regulations time and in a guaranteed perfect machines are delivered to hospitals and handling standards.” Bomi condition, above all when we are and clinics, but also to laboratories “A particular feature of our service Group, with its headquarters in delivering a machine directly to the and research centers. In many cas- portfolio is the ‘cold chain’ service Milan, offers service for machinery operating theater where a patient es, medical devices are transported for goods which need to be kept may be prepared and waiting for directly to patients’ homes, for at a particular, constant tempera- a surgical operation. Often, espe- example in the case of chronically ture both in the warehouse and cially in the case of small hospitals ill people who require apparatus to during transportation. With our and clinics, medical centers have be able to receive treatment while own warehouses and vehicles, we machines delivered for a particular remaining at their own home. This can guarantee this. Other goods Ing. Stefano Camurri: In the logistics business, you have to find your niche. If you want to successfully reduce costs and improve service, you must have the focus of a specialist. aspect makes up around 25% of are particularly large or sensitive Bomi’s current business, and the to movement. We can deal with trend is increasing. all demands. All our drivers are trained for this particular operation Bomi works for the suppliers of and regularly deliver to and collect medical equipment, storing it on from the houses of the patients their behalf and responding imme- and operating theaters. Our staff diately when required to deliver the is also able to offer training to pa- products to a particular location. tients on specific machinery if re- www.european-business.com 18 N A E P O R U E business

Interview with Rob Geraerdts, President for the DACH and Benelux region for the Getinge Group The human face of healthcare Whatever else happens in the world, healthcare is one of the industries that will always be needed. It is a relatively traditional sector and the basic principles underpinning patient care remain fairly constant. Progress is made through advanced treatment techniques and innova- tive products that make life easier and more efficient for patients and medical staff alike. The Getinge Group, headquartered in Sweden, is a leading global provider of innovative solutions for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care and for life science companies and institutions. “Diagnostics look at only a part of Geraerdts has observed that there derstand why this is the case, so tem. “In general, the healthcare the patient, but at Getinge, we see is a high acceptance of innovation, that I can apply this knowledge to sector is under pressure because the patient as a whole individual,” especially in the Benelux region. try to influence the culture in other it is a displacement market. How- explains President of the DACH Belgium in particular invests heav- countries,” he notes. Germany is ever, we are right in the heart of and Benelux region Rob Ger- ily in healthcare, and the Nether- also an important market for Get- Europe and because alternative aerdts. “We look at how a patient lands is very innovative in compari- inge due to its size, although there solutions are welcome here, there is treated and helped to feel hu- son to other European countries. is less scope for experimentation is always potential for growth,” Mr. man again, whether they are in a “One of my challenges is to un- within the German healthcare sys- Geraerdts adds. hospital or a care home. We have a comprehensive portfolio which enables the medical profession to treat the patient holistically. We provide the means to keep eve- rything sterile, the equipment for operating theaters, and facilities for acute care as well as longer term mobility support. This human approach is very important and deeply rooted in the Scandinavian way of doing business.” Although the healthcare market in general is quite traditional, Mr. The Getinge Group is headquartered in Gothenburg, Sweden with sales branches throughout the world N A E P O R U E business Getinge has not lost sight of the need to constantly update its prod- uct portfolio and, in the future, an increased focus will be placed on services. “Up to now, we have always been product oriented,” explains Mr. Geraerdts. “Now it is time to look at technical services that support healthcare outcomes which are becoming much more important and really add value. This means a different way of selling and needs new business models. We will have more of an www.european-business.com 20

Nfood EUROPEAN food blends the flavours of the world with carefully crafted B2B marketing. Our print magazine has been a vital part of A E P O R U E the Anuga for 10 years. This year we are expanding our activities to include opportunities through our website european-food.com, digital editions (ePaper), food newsletter and product presen- tations. We help your company to be a part of the exhibition and enjoy the attention of its international visitors – even if you are not represented with a stand at the Anuga 2017. N A E P O R U E business A N U G A 2 0 1 7 www.european-business.com 22